Is RKLB Stock A Buy Or A High-Beta Trap?
Rocket Lab (RKLB) trades at $66, down 56% from its 52-week high, with a high P/S ratio. Q2 2026 revenue was $234M, up 62% YoY, mainly from Space Systems. Neutron rocket launch and Iridium acquisition are delayed. Backlog is $2.36B. Management expects slow growth from Iridium.
How this was made

The 30-second read
Why it matters
Earnings release provides fresh data on revenue mix and backlog, informing valuation and risk assessment.
Market read
First disclosure of Q2 results; informs short‑ to medium‑term outlook for RKLB and sector peers.
What to watch
Cash burn rate and reliance on a single large Iridium deal not closing until 2027.
Background
Rocket Lab's Q2 2026 earnings report with record revenue but pending milestones.
Ticker impact
Q2 2026 earnings released showing $234M revenue, record quarter, but pending Neutron launch and Iridium acquisition delay.
Modest upside if launch and acquisition close as expected; downside risk if delays persist.
Revenue growth is strong, yet valuation (54x sales) is elevated; future catalysts are uncertain.
Market effects
Highlights challenges for small‑launch providers and satellite manufacturers in a competitive space sector.
Limited to US‑listed aerospace and satellite stocks.
Signals potential slowdown in medium‑lift launch market pending Neutron debut.
Counterpoint
Despite high multiples, the record revenue and backlog may justify premium valuation if execution improves.
Key entities
- CompanyRocket Lab
US‑listed aerospace and satellite manufacturer (ticker RKLB).




